Takeda stock price forecast aligns with Japan’s aging population healthcare demand trend, providing long-term support for revenue expansion across cardiovascular and metabolic products. It is important to consider the total shareholder return, as well as the share price return, for any given stock. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. We note that for Takeda Pharmaceutical the TSR over the last 3 years was 51%, which is better than the share price return mentioned above. This is largely a result of its dividend payments! TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions. Takeda stock price forecast points towards a consolidation phase around ¥4,200 before a potential breakout. Technical charts show 50-day moving average crossing above the 200-day MA, a common bullish signal for pharma equities.
